Corcept Loses Patent Appeal, Generic Threat to Korlym Intensifies

REDWOOD CITY, CA – February 19, 2026 – Corcept Therapeutics saw its stock plummet and its market exclusivity for a flagship drug thrown into question after a federal appeals court dealt the company a significant legal blow. The U.S. Court of Appeals for the Federal Circuit affirmed a lower court's decision that Teva Pharmaceuticals’ generic version of the Cushing’s syndrome treatment, Korlym®, does not infringe on two of Corcept’s key patents.

The ruling sent immediate shockwaves through the market, with Corcept's shares (NASDAQ: CORT) dropping between 15% and 25% in trading as investors grappled with the implications of increased competition for the company's primary revenue driver. The decision marks a critical juncture for Corcept, intensifying the pressure to diversify its portfolio as its hold on the lucrative Cushing’s syndrome market weakens.

A Decisive Legal Setback

The court's decision centers on two Corcept patents (U.S. Patents 10,195,214 and 10,842,800) that describe methods for safely administering Korlym alongside strong CYP3A4 inhibitors—a class of drugs often prescribed to patients with Cushing's syndrome. Corcept argued that Teva's generic would inevitably infringe on these patented methods.

However, the Federal Circuit found no error in the December 2023 ruling by the Federal District Court for the District of New Jersey. The lower court had determined that Corcept failed to prove that physicians were likely to prescribe the drugs in a way that infringed the patents. Crucially, the court noted that Teva's proposed drug label does not encourage or recommend the infringing co-administration; in fact, it includes cautions against it. This distinction proved fatal to Corcept's case.

"We are disappointed in the Court’s ruling," said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer, in a statement. "The patents we asserted in this case cover methods of safely treating patients with Cushing’s syndrome that physicians rely on every day. We will vigorously defend our rights and are currently considering the best way to pursue judicial review of this decision."

For Teva Pharmaceuticals, the ruling removes a major legal barrier. The generic giant received FDA approval for its version of mifepristone (the active ingredient in Korlym) back in August 2020 and officially launched the product on January 19, 2024. This court decision solidifies its position and clears the path for broader market penetration, potentially at a significantly lower price point than the branded therapy.

Korlym's Kingdom Under Siege

The legal defeat is particularly painful for Corcept because of Korlym's central role in its financial health. Approved in 2012, Korlym was the first medication sanctioned by the FDA for endogenous hypercortisolism and has since become the company's flagship product. With a modified 2025 revenue guidance of $800–$850 million, the vast majority of which is tied to Korlym, the threat of generic erosion is substantial.

The market for Cushing’s syndrome treatments is both competitive and growing. Valued at over $4.3 billion in 2025, analysts project the market could expand to nearly $7 billion by 2032. While Corcept once had a pioneering position, it now competes with other branded therapies such as Isturisa (osilodrostat) and Recorlev (levoketoconazole). The full-scale entry of a lower-cost generic from Teva is set to radically alter this landscape, putting downward pressure on pricing and market share for all branded players.

This ruling highlights the perennial challenge for pharmaceutical innovators. Patents are the bedrock of the industry's business model, providing a period of market exclusivity to recoup the enormous costs of research and development. Corcept still holds other patents related to Korlym, including one for optimizing its absorption with food that extends to 2032. However, the loss of the co-administration patents significantly weakens its defensive wall against generic competition.

A Future Beyond Korlym: The Pipeline Pivot

While the legal battle has cast a shadow over its lead product, Corcept has been preparing for this eventuality by investing heavily in its next generation of cortisol modulators. The company's future now rests squarely on the success of its extensive R&D pipeline, led by the promising candidate relacorilant.

Relacorilant, a selective cortisol modulator designed to offer a better safety profile than Korlym, is the cornerstone of Corcept's strategy to pivot away from its reliance on a single product. The company has two critical FDA decision dates on the horizon for the drug: one for hypercortisolism by December 30, 2025, and another for platinum-resistant ovarian cancer by July 11, 2026. Corcept's management has expressed high hopes for relacorilant, projecting it could generate $3 billion to $5 billion in annual revenue from the hypercortisolism indication alone.

Beyond relacorilant, the company is advancing a broad pipeline to demonstrate its long-term viability. This includes:

• Expanded Oncology Programs: Corcept is studying cortisol modulation in earlier-stage ovarian, endometrial, and pancreatic cancers.
• Miricorilant for NASH: A Phase 2b study for non-alcoholic steatohepatitis (NASH) is nearing full enrollment, with initial results expected by late 2026.
• DAZALS for ALS: Despite missing a primary endpoint, exploratory data showing a reduction in mortality at a specific dose has prompted ongoing regulatory discussions.

Fortified by a strong cash position of over $524 million as of late 2025, Corcept is well-funded to pursue these ambitious development programs. The increased spending on R&D and marketing in recent quarters underscores a clear strategy: to build a diversified, multi-product company resilient enough to withstand the inevitable lifecycle of its first-generation drug. The recent court ruling has only made the successful execution of this strategy more urgent.